Drug-induced sleep endoscopy (DISE) has demonstrated that some patients may have the epiglottis playing a significant role in contributing to their obstructive sleep apnea, separate from other structures like the tongue or oropharyngeal lateral walls that secondarily cause airway obstruction behind the epiglottis. The VOTE Classification that Winfried Hohenhorst, Nico de Vries, and I developed…
Nyxoah Genio: DREAM Study Results and FDA Approval!
NOTE: I was a paid Nyxoah consultant, reviewing preoperative drug-induced sleep endoscopy videos for their clinical trials. Based on this work, I was a coauthor on the paper reporting results of the DREAM trial. I have written previously about the Genio system from Nyxoah and aura6000 system from Livanova, including an update on their clinical trials…
Inspire V System now available at UCLA
Hypoglossal nerve stimulation has been a major breakthrough in the treatment of obstructive sleep apnea for patients unable to tolerate positive airway pressure therapy. Inspire Medical Systems had the first technology approved by the US Food and Drug Administration in 2014, and I was the first surgeon in the Western United States to offer this…
Respiratory sensing lead risks with the Inspire IV system
The Upper Airway Stimulation system from Inspire Medical Systems has been an important and effective treatment option for many patients with obstructive sleep apnea. Like any procedure or technology, there are potential important risks to consider. In the United States, the Food and Drug Administration (FDA) maintains the publicly-available Manufacturer and User Facility Device Experience… Read more »
Santa Monica Office
